Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
28 Apr 2020
Historique:
entrez: 12 5 2020
pubmed: 12 5 2020
medline: 12 5 2020
Statut: epublish

Résumé

[This corrects the article DOI: 10.18632/oncotarget.20936.].

Identifiants

DOI: 10.18632/oncotarget.27476 PMID: 32391125 PMC: PMC7197446
pubmed: 32391125
doi: 10.18632/oncotarget.27476
pii: 27476
pmc: PMC7197446
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

1573-1574

Commentaires et corrections

Type : ErratumFor

Informations de copyright

Copyright: © 2020 Borst et al.

Auteurs

Gerben R Borst (GR)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands.

Ramya Kumareswaran (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.

Hatice Yücel (H)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands.

Seyda Telli (S)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.

Trevor Do (T)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.

Trevor McKee (T)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.

Gaetano Zafarana (G)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.

Jos Jonkers (J)

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Molecular Biology, Amsterdam, The Netherlands.

Marcel Verheij (M)

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands.

Mark J O'Connor (MJ)

Oncology, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom.

Sven Rottenberg (S)

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Molecular Biology, Amsterdam, The Netherlands.
Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

Robert G Bristow (RG)

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, Canada.

Classifications MeSH